Private equity firm GTCR announced today that Corza Medical acquired Katena Products and its ophthalmic surgery offerings.
Katena develops ophthalmic products used across cataract, glaucoma and corneal surgeries, including precision surgical instruments, single-use devices and specialty biologics, according to a news release. The company, which has more than 200 employees across North America and Europe, has sold products in more than 110 countries to more than 5,000 customers.
Corza said in the release that the acquisition expands its surgical product portfolio while adding significant scale, product breadth and infrastructure to its ophthalmic surgery segment. It’s the first add-on acquisition for Corza since its formation in January 2021, with the company aiming to take on the “almost monopolistic” leaders in medtech. Corza was formed through the merger of Surgical Specialties and TachoSil, a carve-out from Takeda.
“The addition of Katena is highly complementary to our existing surgical product portfolio,” Corza Executive Chairman Greg Lucier said in the release. “This acquisition underscores our dedication to serving our customers with differentiated, high-performance technologies paired with world-class service. We look forward to continuing to support the Katena customer base and expanding our surgical market presence via continued investment in organic growth and M&A.”
Corza CEO Dan Croteau called Katena a brand with “decades of trust and clinical relevance” in the ophthalmic surgery space.
“Corza is committed to providing exceptional service and value to our customers, transforming surgical outcomes and changing the lives of patients around the globe,” Croteau said. “The acquisition of Katena further enables us to execute on our mission with high-quality products that allow our customers to maintain, improve and restore sight for their patients.”
“Greg, Dan and the Corza team are building a unique platform within the medical technology sector, with an attractive portfolio of growing products in wound closure, biosurgery and ophthalmic,” GTCR Managing Director Sean Cunningham added. “We are excited to continue building out Corza’s portfolio with additional M&A.”
